Here is the effectiveness of Pfizer and Astrazeneca vaccines against the Delta variant
High efficacy Pfizer and AstraZeneca against the Delta variant. Here is what emerges from a new study published in the "New England Journal of Medicine"
Two doses of Pfizer or Astrazeneca vaccine also protect against the Delta variant of Sars-Cov-2 with only a small decrease in efficacy compared to the others. This is demonstrated by data from a new study published in the New England Journal of Medicine .
The study confirms the main findings provided by Public Health England in May on the efficacy of anti-Covid vaccines made by the US company Pfizer with German partner BioNTech and the University of Oxford and the British-Swedish company AstraZeneca.
All the details.
WHAT EMERGED FROM THE PUBLIC HEALTH ENGLAND STUDY
Two doses of Pfizer vaccine were found to be 88% effective in preventing symptomatic disease, compared with 93.7% for Alpha. As for the effectiveness of AstraZeneca, with two doses it was 67%, higher than the 60% reported by other studies, compared to 74.5% for Alfa.
"Only modest differences in vaccine efficacy with the delta variant versus alpha were noted after the two doses," the researchers write.
ONE DOSE IS NOT ENOUGH
The differences are much more marked after receiving a single dose. In fact, the analysis confirmed that a single dose is not enough: for both vaccines the effectiveness of partial immunization stops at around 30%.
HOW THE VARIANTS WERE IDENTIFIED
“Variants were identified with the use of sequencing and on the basis of spike gene status. The data on all symptomatic sequenced cases of Covid-19 in England were used to estimate the proportion of cases with both variants based on the vaccination status of the patients, ”explains the British newspaper.
THE RESULTS OF THE NEW ENGLAND JOURNAL OF MEDICINE STUDY
Overall, therefore, high levels of efficacy of the vaccine against symptomatic disease with the Delta variant were found after administration of two doses.
These estimates are only slightly below the estimate of the vaccine's efficacy against the Alpha variant.
"Our finding of reduced efficacy after the first dose would support efforts to maximize vaccine uptake with two doses among vulnerable groups in the context of Delta variant circulation," the study argues.
THE RESULTS IN CONTRAST WITH THE ISRAELIAN DATA
The UK study is at odds with preliminary data released by the Israeli Ministry of Health earlier this month. According to Israel, the Pfizer-BioNTech vaccine was only 64% effective in preventing symptomatic infection caused by the delta variant. Although the protection against severe disease remains high.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/ecco-lefficacia-dei-vaccini-pfizer-e-astrazeneca-contro-la-variante-delta/ on Thu, 22 Jul 2021 11:14:14 +0000.